Norway Cell Culture Media Market Size & Outlook, 2023-2030
Norway cell culture media market, 2018-2030 (US$M)
Related Markets
Norway cell culture media market highlights
- The Norway cell culture media market generated a revenue of USD 40.4 million in 2023 and is expected to reach USD 81.0 million by 2030.
- The Norway market is expected to grow at a CAGR of 10.4% from 2024 to 2030.
- In terms of segment, serum-free media was the largest revenue generating product in 2023.
- Serum-free Media is the most lucrative product segment registering the fastest growth during the forecast period.
Cell culture media market data book summary
| Market revenue in 2023 | USD 40.4 million |
| Market revenue in 2030 | USD 81.0 million |
| Growth rate | 10.4% (CAGR from 2023 to 2030) |
| Largest segment | Serum-free media |
| Fastest growing segment | Serum-free Media |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Serum-free Media, Classical Media, Stem Cell Culture Media, Chemically Defined Media, Specialty Media, Other Cell Culture Media |
| Key market players worldwide | Sartorius AG, Danaher Corp, Merck KGaA, Thermo Fisher Scientific Inc, FUJIFILM Holdings Corp, Lonza Group Ltd, BD, STEMCELL Technologies, PromoCell GmbH |
Other key industry trends
- In terms of revenue, Norway accounted for 0.9% of the global cell culture media market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK cell culture media market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 670.8 million by 2030.
Serum-free media was the largest segment with a revenue share of 35.4% in 2023. Horizon Databook has segmented the Norway cell culture media market based on serum-free media, classical media, stem cell culture media, chemically defined media, specialty media, other cell culture media covering the revenue growth of each sub-segment from 2018 to 2030.
In December 2022, the national program for clinical treatment research – KLINBEFORSK, allocated research funds to the Haapaniemi group for developing CRISPR-Cas9 gene therapy for STAT1 Gain-ofFunction disease. In addition, in June 2020, Zelluna Immunotherapy, a T Cell Receptor (TCR) cell therapy company, announced the completion of fundraising to focus on the development of its proprietary TCR fully guided Natural Killer (NK) cell therapy platform (TCR-NK) for the treatment of cancers.
Approximately USD 7.5 million has been raised in equity financing and public grants. Zelluna’s strategy is to develop TCR-NK cell therapy products based on its proprietary technology platform, where TCRs are functionally expressed in NK cells.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Culture Media Market Scope
Cell Culture Media Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway cell culture media market size, by product, 2018-2030 (US$M)
Norway Cell Culture Media Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
